Wednesday, November 16, 2022 2:20:56 PM
Thank you for replying to confirm.
Yes, I believe that the confusion might arise from the fact that both Liau and NWBO are involved with murcidencel. This does not mean that Liau is an employee of NWBO—she is not. Dr. Liau is an employee of UCLA.
Dr. Bosch of Northwest Biotherapeutics is one of the coauthors of the murcidencel paper that Dr. Liau will present at SNO, but UCLA is the institution that employs Dr. Liau.
For a complete list of authors, visit the SNO event website: https://soc-neuro-onc.org
https://academic.oup.com/neuro-oncology/article/24/Supplement_7/vii66/6826190?login=false
https://www.uclahealth.org/providers/linda-liau
https://doi.org/10.3171/2020.12.FOCUS20954
https://virtualtrials.org/dcvax.cfm
Yes, I believe that the confusion might arise from the fact that both Liau and NWBO are involved with murcidencel. This does not mean that Liau is an employee of NWBO—she is not. Dr. Liau is an employee of UCLA.
Dr. Bosch of Northwest Biotherapeutics is one of the coauthors of the murcidencel paper that Dr. Liau will present at SNO, but UCLA is the institution that employs Dr. Liau.
For a complete list of authors, visit the SNO event website: https://soc-neuro-onc.org
https://academic.oup.com/neuro-oncology/article/24/Supplement_7/vii66/6826190?login=false
https://www.uclahealth.org/providers/linda-liau
https://doi.org/10.3171/2020.12.FOCUS20954
https://virtualtrials.org/dcvax.cfm
Believe carefully. This is the greatest and most powerful lesson that I have learned since arriving on Earth. Examine what you believe about yourself most importantly, and then believe carefully as you interact with the world.
Recent NWBO News
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 11/26/2025 05:15:34 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
